---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000020"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:23:11.269446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INNOVATE reports Q4 revenue down 34.5% to $236.6M; net loss widens to $16.9M; MediBeacon TGFR receives FDA approval

## Summary
- Q4 2024 revenue $236.6M (-34.5% YoY); net loss attributable to common $16.9M ($1.29 loss per share).
- Full year 2024 revenue $1.11B (-22.2% YoY); Adjusted EBITDA $71.3M (+9.7% YoY).
- Infrastructure segment Q4 revenue $225.7M (-36.2%); adjusted backlog $1.1B; added >$500M to backlog post-year-end.
- MediBeacon TGFR received FDA approval Jan 2025 for kidney function assessment; also NMPA approval in China Feb 2025.
- Broadcasting Q4 revenue $6.8M (+19.3% YoY); Life Sciences revenue $4.1M (R2 unit sales +113% Q4 YoY).

## SEC filing metadata
- accession: 0001006837-25-000020
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000020/0001006837-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000020/hchc-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000020
- JSON: https://secwatch.observer/filing/0001006837-25-000020.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.